To summarize for those who don't want to wade through the wikipedia article, achromatopsia is color blindness resulting from damage to the cortex, the outer layer of the cells in the brain that are generally responsible for all the higher-order processing of the sensory information our nervous system collects. Essentially, this means that your eyes are still functioning normally, but your brain is no longer able to interpret the signals properly; this is normally due to brain damage as result of loss of blood flow, often from a traumatic injury or stroke etc, although there are many other causes, some of which are unknown (idiopathic). This is certainly a different cause of color blindness, but I'm unsure as of why it's being discussed here because the treatments talked about in the article would only correct defects on the functional components of the eye. Correcting a problem in the cortex through a medical treatment is something that is most likely a good ways into the future; it's much more likely that your brain will spontaneously reroute the functional processing to a different undamaged part of the cortex and as a result recover full or partial color vision. If that doesn't happen, which often it doesn't, then it's unlikely that the problem will be fixed.

These are quite exciting developments obviously, especially in regards to the treatment of the myriad of other visual pathologies this approach is applicable to treating. However, the FDA and other relevant medical procedure approving bodies are notoriously against the use of viruses to treat conditions in humans, at least in the US. This is largely due to the nature of viruses; they can mutate rapidly and easily, can quickly become pathogenic, as well as migrate to and interfere with other cells and tissues. I would be somewhat surprised to see a treatment like this based on a viral vector approved even in the medium-term future; most likely the same team or other researchers will develop a different vector that can be proven to be safe and has the ability to more specifically target retinal cells using some sort of CD marker or other retinal-cell specific protein marker. Hopefully this work will be done expeditiously, as these treatments would be a godsend to people suffering from eye pathologies that don't fall within the typical poor eyesight treated by vision correction and/or Lasik.